Gopal AK, Kahl BS, Flowers CR, et al. A phase I trial combining idelalisib, lenalidomide, and rituximab stopped early.65 Similarly, the combination of ibrutinib, lenalidomide, and rituximab also generated unexpected side effects.66. By continuing to use this website you are giving consent to cookies being used. Consequently, the phase III RELEVANCE trial directly compared R2 with immunochemotherapy (R-CHOP, R-bendamustine, or R-CVP).60,61 Final results showed no superiority of R2 compared to standard treatment in the primary endpoints CR at 120 weeks and PFS at 30 months. 43. NIH Follicular lymphoma: evolving therapeutic strategies. Follicular lymphoma is one of the most common non-Hodgkin's lymphomas with an expected survival of more than 20 years for the majority of patients. The 10-year update was recently presented, which confirms a significant improvement regarding the time to next treatment for BR,23 although no difference in overall survival was observed. Novel immunotherapy approaches to follicular lymphoma. A multicenter phase II study of twice-weekly bortezomib plus rituximab in patients with relapsed follicular lymphoma: long-term follow-up. 26. The overall prognosis of patients with follicular lymphoma (FL) has substantially improved over the last decades. Fowler NH, Davis RE, Rawal S, et al. POD24 patients had also an ORR of 49% (CR, 12%). 31. P30 CA008748/CA/NCI NIH HHS/United States, P30 CA086862/CA/NCI NIH HHS/United States, U10 HL069294/HL/NHLBI NIH HHS/United States, U24 CA076518/CA/NCI NIH HHS/United States. Ideally, such new approaches should. Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study. Based on these results, obinutuzumab has been approved for first-line treatment in combination with chemotherapy. Correspondence: Kai Hübel (e-mail: kai.huebel@uni-koeln.de). In recent years there is an increasing understanding on the significance of the microenvironment on lymphoma growth and survival (see above).11 Several compounds directly or indirectly interact with immune cells, blood vessels, or the extracellular matrix surrounding the lymphoma. Heinrich DA, Weinkauf M, Hutter G, et al. Andorsky D, Coleman M, Yacoub A, et al. A total of 28% of patients required dose reductions. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. There is no funding for this work. 44. In the randomized GADOLIN trial, obinutuzumab plus bendamustine was compared with bendamustine alone in relapsed patients who were refractory to rituximab.44 The use of obinutuzumab and bendamustine significantly improved PFS and also OS and clearly demonstrate that obinutuzumab is also active in rituximab-refractory patients.